全球免疫腫瘤精準醫學市場（2023-2030）：最終用戶、癌症類型、治療類型和生物標記的規模、佔有率、成長分析和預測

全球免疫腫瘤精準醫療市場規模預計將從2021年的494億美元成長到2022年的547.4億美元，預測期內年複合成長率為10.8%，到2030年將達到1243.3億美元。 。

全球癌症免疫精準醫學是癌症治療中一個先進且有前景的領域，利用精準和個性化的方法來靶向和根除癌細胞。這種創新方法將免疫療法和精準醫學相結合，旨在提高癌症治療的療效，同時最大限度地減少副作用。新一代測序和生物標記分析等尖端技術在識別特定腫瘤特徵和指導治療決策方面發揮著重要作用。隨著持續的研究和臨床試驗，免疫腫瘤學精準醫學具有巨大的潛力，可以徹底改變癌症治療並改善全世界患者的治療結果。

癌症患病率的不斷上升預計將推動對免疫腫瘤學精準醫療的需求。隨著癌症患者數量的持續成長，人們越來越需要更有效、更有針對性的治療方案。癌症免疫精準醫學提供了根據特定腫瘤特徵和免疫反應為個體患者量身定做癌症治療的可能性。利用免疫系統的力量來對抗癌症，這一新興領域有望改善治療結果並應對不同類型癌症帶來的挑戰。

免疫腫瘤學擴大使用聯合療法與傳統癌症治療（例如化療和放療）一起使用。這種方法因其提高治療效果和對抗治療耐藥性的潛力而受到歡迎。例如，免疫療法和化療的結合在治療某些癌症類型（例如肺癌和黑色素瘤）方面顯示出有希望的結果。化療可以縮小腫瘤，但免疫療法可以幫助患者的免疫系統識別癌細胞並更有效地攻擊它們。

在本報告中，我們研究了全球癌症免疫精準醫學市場，提供了市場概況，分析了市場的各種影響因素、技術和創新趨勢、監管環境、市場規模的轉變和預測以及各個細分市場及地區、細分、競爭格局、主要企業概況等。

目錄

執行摘要

調查方法

母公司市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務

關鍵市場洞察

• 技術分析
• 價格分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 知識產權分析
• 貿易分析
• 啟動分析
• 原料分析
• 創新矩陣
• 管道產品分析
• 宏觀經濟指標
• 主要投資分析
• 關鍵成功因素
• 競爭程度

市場動態及預測

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 監管狀況
• 波特的分析
• Skyquest 對未來顛覆的特別見解

全球免疫腫瘤精準醫學市場（按最終用戶）

• 市場概況
• 醫院
• 診所
• 研究所/其他

全球免疫腫瘤學精準醫學市場，按癌症類型分類

• 市場概況
• 肺癌
• 乳腺癌
• 前列腺癌
• 黑色素瘤/其他

全球免疫腫瘤學精準醫學市場，按治療類型

• 市場概況
• 檢查點抑製劑
• CAR-T細胞療法
• 癌症疫苗
• 其他

全球免疫腫瘤學精準醫學市場：按生物標記分類

• 市場概況
• PD-L1
• BRCA
• KRAS
• EGFR
• 其他

全球免疫腫瘤精準醫學市場（按地區）

• 市場概況
• 北美
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東/非洲

競爭格局

• 前5名企業對比
• 主要企業市場定位
• 各大公司的招聘策略
• 關鍵成功策略
• 近期市場活動
• 主要參與者的市場佔有率

主要公司簡介

• Adaptimmune Therapeutics plc
• Agenus Inc.
• Amgen Inc.
• AstraZeneca plc
• Bristol Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Iovance Biotherapeutics, Inc.
• Juno Therapeutics, Inc.
• Kite Pharma, Inc.
• Merck &Co., Inc.
• Neon Therapeutics, Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Seattle Genetics, Inc.
• Takeda Pharmaceutical Company Limited

Market Insights

Global Precision Immuno-Oncology Market size was valued at USD 49.4 billion in 2021 and is poised to grow from USD 54.74 billion in 2022 to USD 124.33 billion by 2030, growing at a CAGR of 10.8% in the forecast period (2023-2030).

Global Precision Immuno-Oncology is an advanced and promising field in cancer treatment, utilizing precise and personalized approaches to target and eradicate cancer cells. By combining immunotherapy with precision medicine, this innovative approach aims to enhance the effectiveness of cancer treatment while minimizing side effects. Cutting-edge technologies, such as next-generation sequencing and biomarker analysis, play a crucial role in identifying specific tumor characteristics and guiding treatment decisions. With ongoing research and clinical trials, Precision Immuno-Oncology holds great potential in revolutionizing cancer care and improving patient outcomes worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of Precision Immuno-Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Precision Immuno-Oncology Market Segmental Analysis

Precision Immuno-Oncology Market is segmented on the basis of Treatment type, cancer type, end-user, biomarker, and region. By end use, the Precision Immuno-Oncology Market is segmented into hospitals, clinics, research institutes, and others. By cancer type, the Precision Immuno-Oncology Market is segmented into Lung cancer, Breast cancer, Prostate cancer, Melanoma, and others. By treatment type, the Precision Immuno-Oncology Market is segmented into immune checkpoint inhibitors, car T cell therapy, cancer vaccines, and others. By biomarker, the Precision Immuno-Oncology Market is segmented into PD-L1, BRCA, KRAS, EGFR, and others. By region, the Precision Immuno-Oncology Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver

The increasing prevalence of cancer is expected to drive the demand for Precision Immuno-Oncology. As cancer cases continue to rise, there is a growing need for more effective and targeted treatment options. Precision Immuno-Oncology offers the potential to tailor cancer therapies to individual patients based on their specific tumor characteristics and immune responses. By harnessing the power of the immune system to fight cancer, this emerging field holds promise in improving treatment outcomes and addressing the challenges posed by various types of cancer.

Restraints

The growth of the Global Precision Immuno-Oncology market is impeded by the significant cost associated with its implementation. The advanced technologies and personalized nature of precision immuno-oncology therapies can be financially challenging for both healthcare providers and patients. The high cost of treatments may limit accessibility and adoption, hindering the market's potential growth. Addressing these cost-related challenges through research, development, and innovative pricing strategies will be crucial to overcome this restraint and unlock the full potential of precision immuno-oncology in cancer treatment.

Market Trends

In precision immuno-oncology treatments is the increasing utilization of combination therapies alongside traditional cancer treatments like chemotherapy and radiation therapy. This approach has gained popularity due to its potential to enhance treatment effectiveness and combat treatment resistance. For instance, the combination of immunotherapy and chemotherapy has shown promising outcomes in treating certain cancer types like lung cancer and melanoma. While chemotherapy reduces tumor size, immunotherapy helps the patient's immune system recognize and attack cancer cells more effectively.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Precision Immuno-Oncology Market by End use

• Market Overview
• Hospital
• Clinics
• research institutes and others

Global Precision Immuno-Oncology Market by Cancer type

• Market Overview
• Lung cancer
• breast cancer
• prostate cancer
• melanoma and others

Global Precision Immuno-Oncology Market by Treatment type

• Market Overview
• checkpoint inhibitors
• car T cell therapy
• cancer vaccines
• and others

Global Precision Immuno-Oncology Market by Biomarker

• Market Overview
• PD-L1
• BRCA
• KRAS
• EGFR
• and others.

Global Precision Immuno-Oncology Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Adaptimmune Therapeutics plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Juno Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neon Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seattle Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments